In addition, Western blotting results showed that reducing TOP2A increased the expression of Fas, FasL, caspase 8, and caspase 3 (Figure 5F), further suggesting that TOP2A acts as an oncogene by regulating RCC cell proliferation. The gene discussed is CASP3; the disease is renal cell carcinoma.